lipolysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
1787–1797: Self-taught Chinese astronomer Wang Zhenyi published at least twelve books and multiple articles on astronomy and mathematics. Using a lamp, a mirror and a table, she once created a famous scientific exhibit designed to accurately simulate a lunar eclipse. 1786–1797: German astronomer Caroline Herschel discovered eight new comets, along with numerous other discoveries. 1789: French astronomer Louise du Pierry, the first Parisian woman to become an astronomy professor, taught the first astronomy courses specifically open to female students. 1794: British chemist Elizabeth Fulhame invented the concept of catalysis and published a book on her findings. c. 1796–1820: During the reign of the Jiaqing Emperor, astronomer Huang Lü became the first Chinese woman to work with optics and photographic images. She developed a telescope that could take simple photographic images using photosensitive paper. 1797: English science writer and schoolmistress Margaret Bryan published A Compendious System of Astronomy, including an engraving of herself and her two daughters. She dedicated the book to her students.
Unable to afford the TCB Band, the group featured guitarists Jock Bartley and Larry Coryell, Neil Flanz on pedal steel, bassist Kyle Tullis, and drummer N. D. Smart. The touring party also included Parsons' new wife, Gretchen Parsons, who was envious of Harris and her young daughter. Coordinating the spectacle as road manager was Phil Kaufman, who had served time with Charles Manson on Terminal Island but who ensured that the performer stayed clear of drugs and limited his alcohol intake during shows. At first, the band was under-rehearsed and played poorly; however, they improved with steady gigging and received rapturous responses at several counter-cultural venues, including Armadillo World Headquarters in Austin, Max's Kansas City in New York City, and Liberty Hall in Houston, where Neil Young and Linda Ronstadt sat in for a filmed performance. Nevertheless, the tour failed to galvanize sales of GP, which never charted in the Billboard 200. For his next and final album, 1974's posthumously released Grievous Angel, Parsons used Harris and members of the TCB Band. The record received more enthusiastic reviews than GP. Although Parsons only contributed two new songs to the album ("In My Hour of Darkness" and "Return of the Grievous Angel"), he was reportedly enthusiastic with his new sound and seemed to have finally adopted a diligent mindset to his musical career, limiting his intake of alcohol and opiates during most of the sessions. Grievous Angel peaked at number 195 on the Billboard chart.
== Signs and symptoms == The defining sign of kwashiorkor in children is bilateral edema in the feet. Edema may also involve the hands, trunk, and face. Kwashiorkor is characterized by a fatty liver. This fatty liver of the undernutrition phenotype is often accompanied by evidence of inflammation and fibrosis. Whereas a fatty liver of undernutrition is a consistent feature of kwashiorkor, it is only encountered sometimes in children with marasmus. In addition to this characteristic hepatic steatosis, kwashiorkor is marked by a parallel pattern of multi-organ dysfunction. Organs often affected in children with kwashiorkor include the kidneys, pancreas, heart, and nervous system. Other findings that may be encountered on physical exam include a distended abdomen, hair thinning, loss of teeth, skin or hair depigmentation, and dermatitis. Children with kwashiorkor often develop irritability and anorexia. Generally, kwashiorkor is treated by introducing a high-quality source of protein to the diet. Ready-to-use therapeutic food (RUTF) as well as F-100 and F-75 milk powders, which both include skim milk powder, are recommended for the treatment of kwashiorkor. These products are designed for use in low-resource settings. The limited number of kwashiorkor cases that occur in high resource settings, where there is good access to advanced therapeutic tools, are typically treated with partially hydrolyzed or elemental enteral formulas, with parenteral nutrition provided in extreme cases.
Pharmacology is the science of drugs and medications, including a substance's origin, composition and interaction with biological systems; specifically through pharmacokinetics, pharmacodynamics, therapeutic use, and toxicology. The discipline examines these interactions through pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body), both of which determine how a substance alters normal or abnormal biochemical function. Substances with medicinal properties are classified as pharmaceuticals, while the term drug encompasses any chemical agent that alters biological processes. Nanopharmacology is the specialization of pharmacology in the nanoscale. The field encompasses drug composition and properties, functions, sources, medicinal chemistry, drug design, molecular and cellular mechanisms, organ/systems mechanisms, signal transduction/cellular communication, molecular diagnostics, interactions, chemical biology, therapy, medical applications, toxicology, and antipathogenic capabilities. The two main areas of pharmacology are pharmacodynamics and pharmacokinetics. Pharmacodynamics studies the effects of a drug on biological systems, and pharmacokinetics studies the effects of biological systems on a drug. In broad terms, pharmacodynamics discusses the chemicals with biological receptors, and pharmacokinetics discusses the liberation, absorption, distribution, metabolism, and excretion (LADME) of chemicals from the biological systems. Pharmacology is not synonymous with pharmacy, though the two terms are frequently confused.
Sources: en.wikipedia.org
== Derived products == A common method of producing laudanum involves dissolving the PSC or latex-derived opium in alcohol and either allowing the solution to sit for up to a week, being periodically agitated; using fresh alcohol to do multiple washes; or refluxing. The original patents for laudanum in various countries refer to soaking poppy straw with varying levels of pulverisation in plain water for a week then evaporating the water to obtain the gummy or powdery brown concentrate.
==== Therapeutic treatments ==== D-amino acid oxidase is used in therapeutic treatments such as regulation of hormones, regulation of hypertension, treatment of schizophrenia, treatment of psychiatric and cognitive disorders, and possible pain reduction. Changing the amount of D-amino acid oxidase transporters with the use of drugs has therapeutic effects on schizophrenia. D-amino acid oxidase regulates D-aspartate, which regulates the secretion of melatonin, prolactin, testosterone, luteinizing hormone and growth hormone. By regulating D-amino acid oxidase, D-aspartate can also be regulated and control hormone secretion. Increased D-amino acid oxidase activity has been correlated with psychiatric and cognitive disorders, so reducing D-amino acid oxidase can have therapeutic effects on these disorders. D-amino acid oxidase helps produce L-6-hydroxynorleucine, which then generates omapatrilat. Omapatrilat inhibits angiotensin-converting enzyme and neutral endopeptidase and effectively reduces hypertension. D-amino acid oxidase also may have an effect on pain stimuli, but it is not confirmed yet.
== Signs and symptoms == Symptoms include chest pain or angina, shortness of breath, and fatigue. A completely blocked coronary artery will cause a heart attack. Common heart attack symptoms include chest pain or angina, pain or discomfort that spreads to the shoulder, arm, back, neck jaw, teeth or the upper belly, cold sweats, fatigue, heartburn, nausea, shortness of breath, or lightheadedness.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.